Comerica Bank Decreases Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Comerica Bank cut its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 30.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,830 shares of the specialty pharmaceutical company's stock after selling 8,099 shares during the quarter. Comerica Bank owned 0.09% of ANI Pharmaceuticals worth $1,041,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Barclays PLC boosted its position in ANI Pharmaceuticals by 1,681.2% in the third quarter. Barclays PLC now owns 143,033 shares of the specialty pharmaceutical company's stock valued at $8,534,000 after buying an additional 135,003 shares in the last quarter. Franklin Resources Inc. lifted its holdings in ANI Pharmaceuticals by 6.1% in the third quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company's stock valued at $705,000 after buying an additional 691 shares during the period. Assenagon Asset Management S.A. lifted its holdings in ANI Pharmaceuticals by 67.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 311,617 shares of the specialty pharmaceutical company's stock valued at $17,226,000 after buying an additional 125,438 shares during the period. SG Americas Securities LLC bought a new stake in ANI Pharmaceuticals in the fourth quarter valued at $544,000. Finally, Exchange Traded Concepts LLC increased its stake in ANI Pharmaceuticals by 2.6% in the fourth quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company's stock valued at $684,000 after purchasing an additional 310 shares in the last quarter. 76.05% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, SVP Ori Gutwerg sold 881 shares of the business's stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $60.07, for a total value of $52,921.67. Following the transaction, the senior vice president now owns 89,897 shares of the company's stock, valued at approximately $5,400,112.79. The trade was a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Christopher Mutz sold 4,000 shares of the business's stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $60.45, for a total transaction of $241,800.00. Following the completion of the transaction, the insider now directly owns 107,317 shares in the company, valued at $6,487,312.65. This trade represents a 3.59% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 7,681 shares of company stock worth $468,698 over the last three months. 11.10% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP traded up $0.46 during trading hours on Friday, hitting $59.99. 372,976 shares of the company's stock traded hands, compared to its average volume of 298,324. The business's fifty day moving average price is $66.91 and its two-hundred day moving average price is $60.75. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The firm has a market capitalization of $1.31 billion, a P/E ratio of -109.07 and a beta of 0.56. ANI Pharmaceuticals, Inc. has a 52 week low of $52.50 and a 52 week high of $77.00.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its quarterly earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, topping analysts' consensus estimates of $1.37 by $0.33. The business had revenue of $197.12 million during the quarter, compared to analyst estimates of $179.75 million. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company's revenue was up 43.4% on a year-over-year basis. During the same period in the prior year, the business posted $0.82 earnings per share. Equities research analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ANIP. JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 target price for the company. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They issued a "buy" rating and a $80.00 target price on the stock. Truist Financial boosted their target price on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a research note on Monday, April 21st. Guggenheim reaffirmed a "buy" rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, March 17th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $80.13.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.